GlaxoSmithKline Eli Lilly and Genmab-backed messenger RNA drug developer CureVac priced the offering at the top of its range.

Germany-based messenger RNA (mRNA) therapy developer CureVac is floating today in a $213m initial public offering that provides exits for pharmaceutical companies GlaxoSmithKline (GSK), Eli Lilly and Genmab.

The company priced more than 13.3 million shares at the top of the IPO’s $14 to $16 range, valuing it above $2.8bn. It will be listed on the Nasdaq Global Market, and Dietmar Hopp, head of majority shareholder Dievini Hopp BioTech, is buying approximately $118m of shares in the offering.

CureVac is…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn